Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverRXST
HealthcareNGMUSD

RxSight, Inc.

$00123456789.0012345678900123456789-3.4%
52w low (est.) $4.06$6.63 52w high (est.)
Market data · updated 1h ago
Market data
Market cap
USD217.33M
52w range
USD4.48 - USD13.22
Beta
1.15
Sector
Healthcare
Data quality
83/100
Valuation
DCF fair value
USD6.46
Margin of safety
+24.5%
Quality & efficiency
Moat score
35/100
Return on equity
-17.1%
Profit margin
-36.6%
Debt / equity
0.04
Growth & analysts
Revenue growth
-18.5%
Analyst target
USD8.43
Target upside
+62.4%
Analysts
7
Run the 10-point checklist before you buy How these numbers are made

About RxSight, Inc.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Valuation

ValueGrowthProfitHealthIncome38QUALITY
Overall Rating
51
Hold
Hold

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score35
DCF Intrinsic Value
USD6.46+24.5% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD217.33M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
-18.5%
Profit Margin
-36.6%
ROE
-17.1%
Debt / Equity
0.04
Beta
1.15
Beaten Down
vs Healthcare sector:Moat 35 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · RXST